University of Montana Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT01902758
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

University of Montana

Active Ingredients

Drugs in Phase 4 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

menthol (Salonpas) (1 trial)

Drugs in Phase 3 Trials (2)

ambrisentan (letairis) (1 trial)

theophylline (synophylate) (1 trial)

Drugs in Phase 1 Trials (1)

capsaicin (qutenza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Altitude Sickness (Phase 3)

Cough (Phase 1)

Hypersensitivity (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5